Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Matthew J. Frigault, Richard T Maziarz, Jae H. Park, Aleksandr Lazaryan, Nirav N. Shah, Jakub Svoboda, Lazaros J. Lekakis, Ran Reshef, Christine L Phillips, Lea M Burke, Jing Lei, Rodica Morariu-Zamfir, John F. DiPersio

Blood (2023) 142 (Supplement 1): 356.

https://doi.org/10.1182/blood-2023-180205

Published: 2023

Journal Articles

Janus Kinase (JAK) 1 Inhibition Results in Significant Changes in Serum Proteins and Peripheral T-Cell Populations That Correlated with Clinical Scores in Chronic Graft Versus Host Disease (GVHD) Patients (an Analysis from GRAVITAS-309)

Michael Pratta, Angelina Volkova, Maureen Bleam, Rodica Morariu-Zamfir, Beth Rumberger, Stephen Douglass, Susan H. Smith, Valkal Bhatt, John Galvin, Annie Im, Sophie Paczesny, Kirk R. Schultz, Steven Z. Pavletic

Blood (2023) 142 (Supplement 1): 2197.

https://doi.org/10.1182/blood-2023-174955

Published: 2023

Journal Articles

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Annie Im, Daniel Wolff, Corey Cutler, Robert Zeiser, Nirav N. Shah, Ming Tony Tan, Jaime Sanz, Haris Ali, Giuseppe Milone, Arjun D. Law, Domenico Russo, Eva-Maria Wagner, Olga Ivanova, Kevin Hou, Maureen Bleam, Rodica Morariu-Zamfir, Steven Z Pavletic

Blood (2022) 140 (Supplement 1): 1870–1871.

https://doi.org/10.1182/blood-2022-169605

Published: 2022

Journal Articles

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

Michael Pratta, Lea Burke, John F. DiPersio, Richard T. Maziarz, Patricia Feldman, Teresa Brodeur, Cynthia Timmers, Olga Ivanova, April Barbour, Rodica Morariu-Zamfir, Matthew Frigault

Blood (2022) 140 (Supplement 1): 10350–10351.

https://doi.org/10.1182/blood-2022-169382

Published: 2022

Journal Articles

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

Hannah Choe, MD, Nirav N. Shah, MD, Patrice Chevallier, MD PhD, Marie Thérèse Rubio, MD PhD, Mark A. Schroeder, MD, Nancy M. Hardy, MD, Patrick J. Stiff, MD, Carlos Solano, MD PhD, Ibrahim Yakoub-Agha, Jonathan A. Gutman, MD, Scott D. Rowley, MD, Maria Caterina Mico', MD, Elisabetta Terruzzi, MD, Rafael F. Duarte, MD PhD FRCP, Rodica Morariu-Zamfir, MD, Michael Arbushites, Kai Ding, PhD, Miguel-Angel Perales, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-140747

Published: 2020

Journal Articles

Trial in Progress: A Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Annie Im, MD, Rodica Morariu-Zamfir, MD, Maureen Bleam, BS, Ying Yan, PhD, Steven Z. Pavletic, MD MS

Blood (2019) 134 (Supplement_1): 3277.

https://doi.org/10.1182/blood-2019-128586

Published: 2019

Journal Articles

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL

Jennifer R. Brown, Susan O’Brien, C. Daniel Kingsley, Herbert Eradat, John M. Pagel, Jamie Hirata, Tammy McIver, Rodica Morariu-Zamfir, Thomas J. Kipps

Blood (2019) 133 (9): 990–992.

https://doi.org/10.1182/blood-2018-06-857714

Published: 2019

Journal Articles

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Natalie Dimier, Paul Delmar, Carol Ward, Rodica Morariu-Zamfir, Günter Fingerle-Rowson, Jasmin Bahlo, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Jacques J. M. van Dongen, Matthias Ritgen, Sebastian Böttcher, Anton W. Langerak, Michael Kneba, Michael Hallek

Blood (2018) 131 (9): 955–962.

https://doi.org/10.1182/blood-2017-06-792333

Published: 2018

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

Anas Younes, MD, Burke M. John, Catherine S Diefenbach, Silvia Ferrari, Cyrus Kahn, Jeffrey P. Sharman, MD, Monica Tani, Chaitra S. Ujjani, MD, Umberto Vitolo, MD, Sam Yuen, Paul Woodard, Kirsten Mundt, Günter Fingerle-Rowson, Surya Chitra, Gila Sellam, Rodica Morariu-Zamfir, Michael Gilbertson

Blood (2017) 130 (Supplement 1): 481.

https://doi.org/10.1182/blood.V130.Suppl_1.481.481

Published: 2017

Journal Articles

Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase 3 GOYA Trial

Mikkel Z. Oestergaard, Christopher Bolen, Federico Mattiello, Maurizio Martelli, Laurie H. Sehn, MDMPH, Marek Trněný, MD PhD, Alexandar Tzankov, Umberto Vitolo, MD, Tina Nielsen, Rodica Morariu-Zamfir, Günter Fingerle-Rowson, Georg Lenz

Blood (2017) 130 (Supplement 1): 1543.

https://doi.org/10.1182/blood.V130.Suppl_1.1543.1543

Published: 2017

Journal Articles

A Model for Predicting Effect of Treatment on Progression-Free Survival Using Minimal Residual Disease As a Surrogate Endpoint in Chronic Lymphocytic Leukemia

Natalie Dimier, Paul Delmar, Carol Ward, Rodica Morariu-Zamfir, Gunter Fingerle-Rowson, Jasmin Bahlo, Kirsten Fischer, MD, Barbara F. Eichhorst, MD, Valentin Goede, MD, Jacques J.M. van Dongen, MD, Matthias Ritgen, MD, Sebastian Böttcher, MD, Anton W. Langerak, Michael Kneba, Michael Hallek, MD

Blood (2015) 126 (23): 720.

https://doi.org/10.1182/blood.V126.23.720.720

Published: 2015

Journal Articles

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

Anas Younes, MD, Leo Gordon, MD, Stella Kim, MD, Jorge Romaguera, MD, Amanda R Copeland, MS, Silvana de Castro Farial, MD, Larry Kwak, MD, PHD, Luis Fayad, MD, Frederick Hagemeister, MD, Michelle Fanale, M.D., John Lambert, PhD, Teresa Bagulho, MD, Rodica Morariu-Zamfir, MD

Blood (2009) 114 (22): 585.

https://doi.org/10.1182/blood.V114.22.585.585

Published: 2009

Journal Articles

An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).

Ollivier Legrand, MD, Maria B. Vidriales, MD, Xavier Thomas, MD, Charles Dumontet, MD, Anne Vekhoff, MD, Rodica Morariu-Zamfir, MD, John Lambert, MD, Jesus F. San Miguel, MD, Jean-Pierre Marie, MD

Blood (2007) 110 (11): 1850.

https://doi.org/10.1182/blood.V110.11.1850.1850

Published: 2007

Journal Articles

Phase I Study of AVE9633, an AntiCD33-Maytansinoid Immunoconjugate, Administered as an Intravenous Infusion in Patients with Refractory/Relapsed CD33-Positive Acute Myeloid Leukemia (AML).

Francis Giles, MD, Rodica Morariu-Zamfir, MD, John Lambert, MD, Srdan Verstovsek, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Dan Deangelo, MD

Blood (2006) 108 (11): 4548.

https://doi.org/10.1182/blood.V108.11.4548.4548

Published: 2006

NARROW

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Janus Kinase (JAK) 1 Inhibition Results in Significant Changes in Serum Proteins and Peripheral T-Cell Populations That Correlated with Clinical Scores in Chronic Graft Versus Host Disease (GVHD) Patients (an Analysis from GRAVITAS-309)

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

Trial in Progress: A Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase 3 GOYA Trial

A Model for Predicting Effect of Treatment on Progression-Free Survival Using Minimal Residual Disease As a Surrogate Endpoint in Chronic Lymphocytic Leukemia

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).

Phase I Study of AVE9633, an AntiCD33-Maytansinoid Immunoconjugate, Administered as an Intravenous Infusion in Patients with Refractory/Relapsed CD33-Positive Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only